Ozanezumab has been utilized in clinical trials exploring the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Relapsing-Remitting Multiple Sclerosis. The DrugMonitor™ Anti-Ozanezumab Antibody (VS-1224-YC870) is an anti-drug antibody (ADA) against Ozanezumab. This drug-based antibody is raised in mice immunized with the Ozanezumab. The anti-Ozanezumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Ozanezumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-RTN4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-903)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human Nogo-A. It is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis. It targets a protein called Neurite Outgrowth Inhibitor (NOGO-A) or Reticulon 4. NOGO-A is a protein that in humans is encoded by the RTN4 gene that has been identified as an inhibitor of neurite outgrowth specific to the central nervous system. NOGO-A is found at higher than normal levels in persons with MND.
There are currently no Customer reviews or questions for VS-1224-YC870. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.